AOD-9604 and athlete drug testing: what's actually detected

Last updated 2026-07-25

Is AOD-9604 banned for athletes?

Yes. AOD-9604 is a fragment of human growth hormone, and growth hormone and its releasing factors sit on WADA's Prohibited List in the peptide hormones category. It doesn't matter that AOD-9604 was developed as an obesity drug rather than a muscle-building one. The ban covers the class of molecule, not the marketing pitch. This matters because a lot of people assume a fragment peptide, something that's only 15 amino acids long instead of the full 191 in real hGH, might slip under the radar or not count as "real" growth hormone. It counts. Anti-doping labs treat GH fragments and analogs as prohibited substances, and that's been the working assumption in the sports drug testing literature for over a decade ^{[1] [2]}. If you're an athlete subject to testing, in-competition or out-of-competition, using AOD-9604 is a doping violation risk regardless of whether you get caught. That's a separate question from whether current tests can detect it, which is where things get more interesting. See our full breakdown on how AOD-9604 dosing actually works if you're weighing research use against that risk. Our companion piece on AOD-9604 storage and shelf life covers the handling side for anyone researching the compound regardless of the testing question.

Does AOD-9604 show up on a standard hGH test?

A 2013 study specifically asked whether AOD-9604 interferes with the WADA hGH isoform immunoassay, the test labs actually use to catch growth hormone doping. The finding: it doesn't. The paper concluded AOD-9604 "does not influence the WADA hGH isoform immunoassay" ^[3]. That's a narrow, specific result and worth being precise about. The hGH isoform test works by comparing ratios of different growth hormone isoforms in blood, a signature that shifts when someone injects recombinant hGH (which is a single isoform) versus the mix your pituitary naturally makes. AOD-9604 isn't full-length hGH, so it doesn't move that ratio the way real GH doping does. The study isn't saying AOD-9604 is undetectable by any method. It's saying one specific, widely used immunoassay doesn't pick it up. That distinction gets lost a lot in forum discussions, where people shorten "doesn't trigger the hGH isoform test" into "undetectable." Those are not the same claim, and the second one is increasingly untrue as testing labs add peptide-specific methods.

Can labs detect AOD-9604 directly, even if the hGH test misses it?

Increasingly, yes. Anti-doping science has moved well past relying on a single immunoassay for everything. Mass spectrometry methods built specifically to catch small peptides have gotten a lot better since 2013. One method, published in the Journal of Separation Science in 2016, describes a way to screen for peptides under 2 kDa (AOD-9604 is roughly 1.8 kDa) by injecting urine directly into a liquid chromatography and ion mobility mass spectrometry setup ^[4]. That's a workflow built specifically to catch small peptide fragments that older methods, tuned for bigger protein hormones, would walk right past. Separately, review papers on detecting peptidic drugs and "drug candidates and analogs" in doping control describe the general strategy: labs don't just look for approved drugs, they build reference libraries for peptides still in development or those, like AOD-9604, that never made it to approval anywhere ^{[2] [1]}. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis on detecting "emerging therapeutics and non-approved drugs" makes the same point: testing labs actively chase substances precisely because they're obscure and might be used to dodge established tests ^[1]. The practical upshot: the fact that a 2013 immunoassay study didn't flag AOD-9604 doesn't mean testing has stayed frozen in 2013. Assume any anti-doping lab running current LC-MS peptide panels has AOD-9604 in its target list or could add it without much trouble.

What does the human trial evidence on AOD-9604 actually show?

This is the part that should matter more to most readers than the testing question, honestly. AOD-9604 went through obesity drug development, including registered trials, and the fat-loss results did not clearly separate from placebo. A 2004 review in Current Opinion in Investigational Drugs covering AOD-9604's metabolic profile is one of the earliest published looks at the compound as a fat-loss candidate ^[5]. A 2006 review of obesity drugs in clinical development situates AOD-9604 among a crowd of compounds being tested for weight loss around that period ^[6]. Neither of these gives AOD-9604 a clean, unambiguous win over placebo for body fat reduction. The trial registration record backs this up. Entries under "Gateways to clinical trials" in Methods and Findings in Experimental and Clinical Pharmacology from 2003 and 2005 list AOD-9604 among compounds moving through registered development ^{[7] [8] [9]}, but the compound never reached approval anywhere. No regulatory body, not the FDA, not any equivalent agency abroad, has approved AOD-9604 for obesity, fat loss, or any other indication. You can check that directly in Drugs@FDA, the FDA's own database of approved products ^[10]: AOD-9604 isn't in it. That's the honest state of the evidence. A fragment of hGH, tested in humans for obesity, that didn't produce a convincing separation from placebo and never cleared approval. If you're chasing fat loss with real trial support behind it, AOD-9604 is not where the strongest data lives. Our separate piece on AOD-9604 storage and shelf life covers the practical handling side if you're researching the compound anyway.

Why was AOD-9604 designed the way it is?

The rationale isn't crazy, it's just unproven in practice. Growth hormone has a fat-metabolizing effect that lives in a specific region of the molecule, the C-terminal fragment, roughly amino acids 177 to 191. Full-length hGH also drives growth and insulin resistance effects through other parts of the molecule, effects nobody wants in a fat-loss drug. The idea behind AOD-9604 was to isolate just that fat-metabolizing fragment and leave the growth-promoting parts out. On paper, that's a smart design goal: keep the lipolytic activity, drop the side effects tied to GH's growth-hormone-receptor activation elsewhere on the molecule. The problem is that a good rationale for a drug candidate and a good clinical trial result are two different things. Plenty of drugs with clean mechanistic stories fail in humans anyway, because biology is messy and a plausible mechanism doesn't guarantee a measurable effect at a tolerable dose. AOD-9604's development history is a real-world example of exactly that gap. The 2004 metabolic review ^[5] and 2006 obesity drug pipeline review ^[6] cover the compound at the stage where this rationale was being tested against real outcomes, and the outcomes didn't confirm the theory cleanly. If you want the dosing background behind that rationale, our guide on how to reconstitute AOD-9604 walks through it.

Does AOD-9604 show up in newer peptide research outside of the fat-loss angle?

Yes, and it's worth knowing where. Recent literature on therapeutic peptides has looked at AOD-9604 and related fragments in orthopaedic and musculoskeletal contexts, separate from the original obesity angle. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics broadly, including applications, challenges, and open questions for this drug class ^[11]. A companion 2026 paper in Sports Medicine looks specifically at safety and efficacy questions for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[12]. That paper's framing is useful context for anyone in sport considering AOD-9604: it treats unapproved peptides as a category athletes are using for injury recovery and performance, with the safety and efficacy data lagging behind the enthusiasm. Neither of these papers overturns the earlier obesity trial record. They're evidence the peptide research world hasn't stopped looking at AOD-9604 and fragments like it, but for a different application than the original fat-loss pitch, and still without approval anywhere.

What happens if AOD-9604 is found in a drug test?

If a lab's peptide screening panel picks up AOD-9604 in a sample, and it can, given the direct-injection LC-MS methods described above ^[4], that's treated the same as any other prohibited substance finding: an adverse analytical finding under the athlete's governing anti-doping code. The specific consequences (suspension length, appeals process) run through each sport's anti-doping rules, and those vary by federation and by whether it's a first offense. What's consistent across the literature is that anti-doping science treats AOD-9604 as a member of the prohibited GH-fragment/analog category, not as some gray-area substance that needs a special ruling each time. The 2014 review on detecting peptidic drug candidates and analogs makes clear that labs actively build detection methods around exactly this kind of "analog of a banned hormone" logic ^[2]. There's no dose or timing trick that reliably beats this. Detection windows for small peptides depend on dose, clearance rate, and which specific assay a lab runs on a given sample, and none of that is public, verified information you should plan around.

How is AOD-9604 usually sourced, and does that affect legal status for athletes?

AOD-9604 is not an FDA-approved drug. It doesn't appear in Drugs@FDA ^[10], and it's not on either FDA bulk drug substance list used for lawful compounding, the 503A list under 21 CFR 216.23 or the 503B list under 21 CFR 216.24. Those two lists (21 CFR 216.23 and 216.24) are the FDA's mechanism for allowing certain unapproved bulk substances into compounded prescriptions under 21 U.S.C. 353a, and AOD-9604 isn't on either one. What that means practically: research-grade AOD-9604 sold online is sold for laboratory research use, not for human injection, and any use in a person, athlete or not, falls outside FDA-sanctioned use categories entirely. Sourcing has zero bearing on anti-doping status. A compound is banned in sport based on what it is (a GH fragment/analog) and what it's promoted or intended to do, not on whether it came from a pharmacy, a compounder, or a research supplier. FDA's own guidance on "intended use" under 21 CFR 201.128 makes clear that marketing and context, more than the label, determine what a product is treated as legally. If you're an athlete weighing any peptide, AOD-9604 or otherwise, the responsible move is checking your sport's specific prohibited list and talking to your federation's anti-doping program before use, not assuming an unregulated source makes the substance invisible to testing. If you do handle it as a research compound, our guides on reconstituting AOD-9604 and storing it properly cover the practical side, separate from the legal and testing questions here.

How does AOD-9604 compare to other fat-loss options with stronger trial data?

This is worth being blunt about. If the goal is fat loss backed by trials that actually separated from placebo convincingly and led to real approvals, AOD-9604 isn't the strongest option on the table. It's a compound whose defining human trial data, per the 2004 and 2006 reviews covering it ^{[5] [6]}, didn't clear that bar, and it has no FDA approval for any indication ^[10].

That table isn't a knock against the underlying idea of targeting the fat-metabolizing region of growth hormone. It's a statement about where the actual clinical evidence landed. If you want peer-reviewed clinical trial support for fat loss, the approved GLP-1 class has it in a way AOD-9604 doesn't. If you're specifically researching AOD-9604 for other reasons (peptide research, injury-related interest per the 2026 orthopaedic and sports medicine reviews ^{[11] [12]}), go in knowing the obesity claim specifically rests on weak human data.

What should someone considering AOD-9604 for research actually do?

Read the primary trial-era literature yourself rather than trusting summaries on forums or seller pages. The 2004 metabolic review ^[5] and 2006 obesity pipeline review ^[6] are short, technical, and give you the actual state of the evidence without marketing language layered on top. If you're handling AOD-9604 as a research compound, proper reconstitution and storage matter for keeping the peptide stable, separate from any question about whether it works. See how to reconstitute AOD-9604 and AOD-9604 storage and shelf life for the practical side of that. For sourcing decisions specifically, going through a provider-reviewed pathway matters more than most people realize, since research peptide quality control varies enormously between suppliers. AOD-9604 Co's provider-reviewed listings route through a named fulfilling pharmacy partner rather than anonymous suppliers, which is the more accountable way to source if you're going to use this compound at all. If you're an athlete under any testing jurisdiction, the calculus is simpler: the trial evidence for fat loss is weak, the substance is banned regardless of that weak evidence, and current peptide-specific testing methods are actively built to catch exactly this kind of small fragment ^[4]. The risk-reward math doesn't favor use.

Frequently asked questions

Does AOD-9604 show up on a standard growth hormone drug test?

A 2013 study found AOD-9604 does not affect the WADA hGH isoform immunoassay, the standard test for GH doping ^[1]. That doesn't mean it's undetectable overall. Dedicated small-peptide mass spectrometry methods, including direct urine injection LC-MS approaches published in 2016, are built to catch peptides in AOD-9604's size range ^[7].

Is AOD-9604 banned by WADA?

AOD-9604 is a fragment/analog of human growth hormone, and GH and its fragments and releasing factors sit in the peptide hormones category on WADA's Prohibited List. Anti-doping literature consistently treats GH fragments and analogs as prohibited regardless of whether the specific compound is FDA-approved or marketed for a non-performance purpose like fat loss ^[4][5].

Has AOD-9604 ever been approved by the FDA for weight loss?

No. AOD-9604 does not appear in Drugs@FDA, the FDA's database of approved drug products ^[13]. It went through obesity-focused development and trial registration in the early-to-mid 2000s ^{[8][9][10][11][12]}, but never reached approval anywhere, and it isn't on FDA's 503A or 503B bulk drug substance lists used for lawful compounding either.

Did AOD-9604 actually work in human obesity trials?

The published record doesn't support a clean win. A 2004 review of AOD-9604's metabolic effects ^[8] and a 2006 review of the obesity drug pipeline that included AOD-9604 ^[9] don't describe results that clearly separated from placebo. That's the central, honest fact about this compound's human trial record.

Why was AOD-9604 designed as a fragment instead of using full hGH?

Full-length growth hormone drives fat metabolism through one region of the molecule and growth/insulin-resistance effects through others. AOD-9604 isolates roughly the C-terminal 15 amino acids (around positions 177-191) to try to keep the fat-metabolizing activity while dropping the growth-related side effects. The rationale is sound; the human trial results didn't confirm it worked as intended ^[8][9].

Can anti-doping labs detect small peptides like AOD-9604 in urine?

Yes, increasingly well. A 2016 method in the Journal of Separation Science describes screening peptides under 2 kDa, AOD-9604's size range, by direct urine injection combined with liquid chromatography and ion mobility mass spectrometry ^[7]. Broader reviews on detecting peptidic drug candidates in doping control describe labs actively building reference libraries for exactly these obscure, unapproved peptides ^[4][5].

Is AOD-9604 the same thing as HGH?

No. AOD-9604 is a synthetic fragment representing roughly amino acids 177-191 of the 191-amino-acid human growth hormone molecule, not the full hormone. It was designed to isolate GH's fat-metabolizing activity, but it's a distinct, much smaller molecule (about 1.8 kDa versus full hGH) with a different testing and regulatory profile ^[1][8].

What happens if AOD-9604 is found in an athlete's sample?

It's treated as an adverse analytical finding for a prohibited substance, the same category as other banned GH fragments and analogs. Specific consequences run through each sport's anti-doping code and vary by federation. The scientific literature treats detection of GH analogs like AOD-9604 as a standard target for modern peptide-screening methods ^[4][7].

Does buying AOD-9604 as a 'research chemical' make it legal for athletes to use?

No. Sourcing has no bearing on anti-doping status. AOD-9604 is banned based on what the molecule is (a GH fragment/analog), not on how it's sold or labeled. It's also not on either FDA bulk drug substance list for lawful compounding (21 CFR 216.23 or 216.24), and it's not approved for human use for any indication.

Is there newer research on AOD-9604 outside the obesity angle?

Yes. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides, including AOD-9604-type fragments, in orthopaedic applications ^[14]. A companion 2026 Sports Medicine review looks at safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance ^[15].

How is AOD-9604 different from GLP-1 drugs like semaglutide for fat loss?

GLP-1 receptor agonists have FDA-approved products for weight management, backed by registration trials that showed clear separation from placebo, per Drugs@FDA ^[13]. AOD-9604 has neither approval nor a clean placebo-separating trial result in the reviewed literature ^[8][9]. They're not comparable in strength of evidence.

Does AOD-9604 interfere with any other doping tests besides the hGH isoform test?

The 2013 study specifically addressed the WADA hGH isoform immunoassay and found no interference ^[1]. It did not test every possible anti-doping assay. Broader peptide-detection reviews suggest labs use multiple complementary methods, including direct LC-MS peptide screening, so a compound clearing one assay doesn't mean it clears all testing approaches ^[4][5][7].

Sources

1. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay used to detect growth hormone doping
2. PubMed, Journal of Separation Science (2016): A method using direct urine injection with LC and ion mobility mass spectrometry screens for peptides under 2 kDa, the size range including AOD-9604
3. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Anti-doping analytical methods target emerging therapeutics and non-approved drugs, more than approved substances
4. PubMed, Expert Review of Proteomics (2014): Doping control labs build detection methods for peptidic drugs, drug candidates, and analogs, including unapproved compounds
5. PubMed, Current Opinion in Investigational Drugs (2004): Review of AOD-9604's metabolic profile from its obesity drug development period
6. PubMed, Current Opinion in Investigational Drugs (2006): Review of obesity drugs in clinical development in 2006, including AOD-9604's place in that pipeline
7. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Trial registration listing showing AOD-9604 among compounds in registered clinical development in 2003
8. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Additional 2003 trial registration listing covering AOD-9604's development stage
9. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): 2005 trial registration listing showing continued development tracking of AOD-9604
10. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product for any indication
11. PubMed, JAAOS Global Research & Reviews (2026): Review of therapeutic peptides in orthopaedics covering applications and challenges for peptides including AOD-9604-type fragments
12. PubMed, Sports Medicine (2026): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance